Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Covalent antithrombin-heparin complexes.

S Patel1, L R Berry, A K C Chan

  • 1Henderson Research Centre, McMaster University, Hamilton, Ontario, Canada.

Thrombosis Research
|September 19, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient Experiences of Using Wearable Health Monitors During Cancer Treatment: A Qualitative Study.

Clinical oncology (Royal College of Radiologists (Great Britain))·2024
Same author

Managing acute myocardial infarction in patients with COVID-19 at a cardiac catheterisation laboratory.

Hong Kong medical journal = Xianggang yi xue za zhi·2021
Same author

Results of a multinational survey of diagnostic and management practices of thromboembolic pulmonary embolism in children.

Thrombosis research·2019
Same author

Relation between HbA<sub>1c</sub> and incident cardiovascular disease over a period of 6 years in the Hong Kong population.

Diabetes & metabolism·2018
Same author

Impact of baseline clinical and laboratory features on the risk of thrombosis in children with acute lymphoblastic leukemia: A prospective evaluation.

Pediatric blood & cancer·2018
Same author

Recommendations for future research in relation to pediatric pulmonary embolism: communication from the SSC of the ISTH.

Journal of thrombosis and haemostasis : JTH·2017
Same journal

Apoptotic versus procoagulant platelets: similar "necrotic" phenotype and procoagulant activity in vitro, but distinct adhesive protein composition.

Thrombosis research·2026
Same journal

Heatstroke-induced coagulopathy: A scoping review of therapeutic strategies and outcome reporting.

Thrombosis research·2026
Same journal

Mapping thrombus habitat: Non-contrast MRI radiomics and pixel-tile histomics approach to track venous thrombosis evolution in mice.

Thrombosis research·2026
Same journal

A study protocol for a randomised controlled trial evaluating the safety and efficiency of the YEARS algorithm versus computed tomography pulmonary angiography only for suspected acute pulmonary embolism in patients with cancer: the Hydra Study.

Thrombosis research·2026
Same journal

Associating the phenotypic expression of platelets with disease type through image-based single-cell profiling.

Thrombosis research·2026
Same journal

The mechanisms of contractile dysfunction following chronic limited platelet activation in (pro)thrombotic conditions.

Thrombosis research·2026
See all related articles

New covalent antithrombin-heparin (ATH) complexes show improved anticoagulant properties over unfractionated heparin (UFH) and low molecular weight heparin (LMWH). These novel ATH agents offer enhanced thrombin inhibition and better safety profiles for thrombosis treatment.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Hematology

Background:

  • Unfractionated heparin (UFH) and low molecular weight heparin (LMWH) are standard anticoagulants but have limitations.
  • Biophysical and safety concerns necessitate the development of novel anticoagulant therapies.
  • Covalent antithrombin-heparin (ATH) complexes represent a promising alternative to existing heparins.

Purpose of the Study:

  • To evaluate the properties of a novel covalent antithrombin-heparin (ATH) conjugate developed by Chan et al.
  • To compare the efficacy and safety of this new ATH conjugate against traditional heparins.
  • To assess the potential of ATH for controlling clot propagation.

Main Methods:

  • Preparation and characterization of the novel ATH conjugate.

Related Experiment Videos

  • Assessment of direct thrombin inhibition rates and catalytic activity.
  • Evaluation of anti-factor Xa activity and inhibition of clot-bound thrombin.
  • Comparison of antithrombotic efficacy and bleeding profiles in preclinical models.

    • Main Results:

    • The Chan et al. ATH conjugate demonstrated increased direct thrombin inhibition rates.
    • ATH exhibited high specific activity in catalyzing coagulant enzyme inhibition by antithrombin.
    • Unlike UFH, ATH effectively inhibited clot-bound thrombin.
    • At equivalent antithrombotic efficacy, ATH showed improved bleeding profiles compared to heparins.

    Conclusions:

    • The novel ATH conjugate possesses superior anticoagulant properties compared to UFH and LMWH.
    • ATH demonstrates enhanced efficacy in inhibiting thrombin, including clot-bound thrombin.
    • Preclinical data suggest that ATH warrants clinical investigation for thrombosis management.